<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703894</url>
  </required_header>
  <id_info>
    <org_study_id>AY:CAR</org_study_id>
    <nct_id>NCT04703894</nct_id>
  </id_info>
  <brief_title>Tolerance and Acceptability Evaluation AYMES Cardiff</brief_title>
  <official_title>Tolerance and Acceptability Evaluation AYMES Cardiff</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aymes International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aymes International Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate tolerance and acceptability of 'CARDIFF' in patients requiring supplementary oral&#xD;
      nutritional support compared with currently available alternatives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate tolerance and acceptability of 'CARDIFF' in patients requiring supplementary oral&#xD;
      nutritional support compared with currently available alternatives, measuring outcomes of GI&#xD;
      effects, Compliance, product preference, convenience etc.&#xD;
&#xD;
      To obtain data to support an ACBS submissions for 'CARDIFF' (to allow for prescription in the&#xD;
      community at NHS expense).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Actual">January 13, 2020</completion_date>
  <primary_completion_date type="Actual">January 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastro-Intestinal Tolerance when consuming AYMES CARDIFF</measure>
    <time_frame>30 days</time_frame>
    <description>To assess gastro-intestinal tolerance of 'CARDIFF' in patients in the community requiring oral nutritional supplementation. Monitoring includes recording the number of any GI complaints via a daily diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability and Palatability of Consuming the Nutritional Supplement: questionnaire</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the acceptability of 'CARDIFF' in patients in the community requiring oral nutritional supplementation. At the end of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new supplement drink. A 5 point hedonic scale will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the compliance of patients to 'CARDIFF' by daily completion of a compliance diary, comparing consumed versus prescribed amount.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>AYMES 'CARDIFF'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'CARDIFF' for a period of 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AYMES 'CARDIFF'</intervention_name>
    <description>AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.</description>
    <arm_group_label>AYMES 'CARDIFF'</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients.&#xD;
&#xD;
          -  ≥ 18 years of age.&#xD;
&#xD;
          -  Patients of the intended target group (e.g. MUST score ≥ 1) with an anticipated period&#xD;
             of nutritional support ≥ 30 days.&#xD;
&#xD;
          -  Patient is able and willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with medical or dietary contraindication to any feed ingredients.&#xD;
&#xD;
          -  Patients requiring sole enteral tube feeding or parenteral nutrition.&#xD;
&#xD;
          -  Patients with significant renal (requiring dialysis) or hepatic impairment (e.g.&#xD;
             hepatitis.)&#xD;
&#xD;
          -  Patients with dysphagia requiring levels 1, 2, 3 or 4 thickened fluids.&#xD;
&#xD;
          -  Patients with uncontrolled inflammatory bowel disease or previous bowel resection with&#xD;
             ongoing gastrointestinal symptoms.&#xD;
&#xD;
          -  Patients for whom the investigator has concerns regarding the ability or willingness&#xD;
             of the patient and or carer to comply with protocol requirements.&#xD;
&#xD;
          -  Participation in any other studies involving investigational or marketed products&#xD;
             concomitantly or within 2 weeks prior to entry into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AYMES International Ltd.</name>
      <address>
        <city>Haywards Heath</city>
        <zip>RH16 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

